Research programme: multiple sclerosis therapies - BiogenAlternative Names: BIIB 053; Death receptor-6 antagonists - Biogen; DR6 antagonists - Biogen Idec
Latest Information Update: 09 Apr 2015
At a glance
- Originator Biogen Idec
- Developer Biogen
- Mechanism of Action Death domain receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 05 Aug 2014 Preclinical development is ongoing in USA